Summary by Moomoo AI
On April 10, 2024, Vertex Pharmaceuticals Incorporated (Vertex) announced its entry into a Merger Agreement with Alpine Immune Sciences, Inc. Under the agreement, Vertex's wholly owned subsidiary, Adams Merger Sub, Inc., will initiate a cash tender offer to acquire all outstanding shares of Alpine Immune Sciences at $65.00 per share. The offer is contingent upon a majority of Alpine's shares being tendered, regulatory approvals, and other customary conditions. The tender offer will commence within 10 business days from the agreement date and will expire 20 business days after its commencement, unless extended. Following the offer's completion, Alpine will merge with Adams Merger Sub, Inc., becoming a wholly owned subsidiary of Vertex. The merger is not subject to a financing condition. In conjunction...Show More